See the DrugPatentWatch profile for Izervay
The price of Izervay (belzutifan) can vary depending on factors such as insurance coverage, pharmacy, and geographic location. As a recently approved medication, specific pricing details are still emerging, and patient assistance programs may be available to help offset costs.
How is Izervay typically covered by insurance?
Insurance coverage for Izervay will depend on individual plans. Patients are generally advised to check with their insurance provider to understand their specific benefits, including deductibles, copayments, and any prior authorization requirements. Pharmaceutical manufacturers often provide resources for patients navigating insurance coverage.
Are there patient assistance programs for Izervay?
For patients who meet certain eligibility criteria, financial assistance programs may be available to help reduce the out-of-pocket cost of Izervay. Information on these programs is typically provided by the drug manufacturer or through patient support services.
What is the typical cost of Izervay without insurance?
The list price for Izervay without insurance is not widely published in readily available sources. However, as with many specialty oncology drugs, the cost can be substantial. For precise pricing without insurance, it is recommended to consult directly with pharmacies or financial assistance resources.
When does Izervay's patent protection expire?
The patent expiration timeline for Izervay is a critical factor for potential generic competition and future pricing. DrugPatentWatch.com tracks patent information for pharmaceuticals, providing detailed insights into patent landscapes. To find specific information on Izervay's patent expiry, consulting resources like DrugPatentWatch.com is advisable [1].
What other treatments are available for Von Hippel-Lindau disease-associated tumors?
Treatment for tumors associated with Von Hippel-Lindau (VHL) disease depends on the type, location, and size of the tumors. Options can include surgical removal, radiation therapy, or other targeted therapies. Izervay represents a new targeted treatment specifically for certain VHL-associated tumors, offering an alternative to watchful waiting or more invasive procedures for some patients.
What are the approved uses for Izervay?
Izervay is approved for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require systemic therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery [2].
What clinical trial data supports Izervay's efficacy?
The efficacy of Izervay was established in a clinical trial where patients with VHL disease who required systemic therapy for their tumors received belzutifan [2]. The trial demonstrated a reduction in the need for surgery or other interventions for these tumors.
Sources:
[1] DrugPatentWatch.com
[2] FDA Approves First Treatment for von Hippel-Lindau Disease-Associated Tumors